-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The First Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference was held, and Shijiazhuang Fourth Pharmaceutical Group was invited to attend and showcase its innovative achievements.
Category:
Time：2023-06-19
From June 17 to 18, the first Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference, jointly hosted by the Hebei Provincial Pharmaceutical Association, the Beijing Pharmaceutical Association, and the Tianjin Pharmaceutical Association, and co-sponsored by the Chinese Pharmaceutical Association, the Management Committee of the Xiong'an New Area, and the Hebei Provincial Association for Science and Technology, was held in the Xiong'an New Area. Shijiazhuang Siyao Group attended the conference as a co-organizer of the inaugural meeting of the Professional Committee on Intravenous Medication Preparation and Management of the Chinese Pharmaceutical Association, as well as the special seminar on “Rational Drug Use Management and Practice.”
From June 17 to 18, the first Beijing-Tianjin-Hebei Pharmaceutical Innovation and Development Conference, jointly hosted by the Hebei Provincial Pharmaceutical Association, the Beijing Pharmaceutical Association, and the Tianjin Pharmaceutical Association, and co-sponsored by the Chinese Pharmaceutical Association, the Xiong’an New Area Administration Committee, and the Hebei Provincial Association for Science and Technology, was held in the Xiong’an New Area. Shijiazhuang Fourth Pharmaceutical Group attended the conference as a co-organizer of the inaugural meeting of the Professional Committee on Intravenous Medication Compounding Management of the Chinese Pharmaceutical Association, as well as the special seminar on “Rational Drug Use Management and Practice.”
It is understood that the purpose of this conference is to further promote coordinated development among Beijing, Tianjin, and Hebei, as well as to build a high-level innovation platform for biomedicine. The conference aims to explore close integration among talent chains, innovation chains, and industrial chains, accelerate the completion, extension, and strengthening of strategic emerging industries in biomedicine across the Beijing-Tianjin-Hebei region, deepen the integrated development of industry, academia, research, and application in the region, boost the commercialization of biomedical scientific and technological achievements, and support the relocation of non-capital functions from Beijing.
As a high-profile national event dedicated to the innovative development of the pharmaceutical industry, the conference was attended by leading officials including Bi Jingquan, member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and vice chairman of the CPPCC Economic Committee; Sun Xianze, president of the Chinese Pharmaceutical Association; and Zhang Boli, an academician of the Chinese Academy of Engineering, as well as renowned academicians, experts, and scholars from China’s pharmaceutical sector, leaders from government departments in the Beijing-Tianjin-Hebei region, representatives from prominent pharmaceutical companies, and specialists from medical institutions. Zhen Zhanjun, executive president of Shijiazhuang No.4 Pharmaceutical Group, and Wei Saili, deputy general manager of the R&D center at Shijiazhuang No.4 Pharmaceutical Group, were invited to participate in several high-level academic conferences. There, they engaged in extensive exchanges with attending experts and industry representatives, jointly exploring new models for the innovative development of the pharmaceutical industry in the Beijing-Tianjin-Hebei region.
In the corporate image display area, Shijiazhuang No.4 Pharmaceutical Company showcased its R&D innovation achievements and newly approved products over the past two years. Among these were the dual-valve, easy-to-break, upright polypropylene infusion bags; dual-lumen, non-PVC multilayer co-extruded film infusion bags; Bunanox tablets; and pentoxifylline injection (sustained-release tablets), as well as several therapeutic products—such as argatroban injection and bromhexine hydrochloride injection—that have recently been added to the national centralized procurement catalog. These products attracted close attention from attending experts, fostered stronger industry collaboration and exchange, enhanced the brand image of Shijiazhuang No.4 Pharmaceutical Company, and further boosted confidence in mutual cooperation.
As a leading enterprise in China’s large-volume parenteral solutions production, R&D, and export sectors, Shijiazhuang Fourth Pharmaceutical Group has consistently adhered to an innovation-driven development philosophy. Its soft-bag IV solutions now account for “half of the market” in the nationwide market for similar products. Particularly over the past two years, Shijiazhuang Fourth Pharmaceutical has aligned its innovation chain with the industrial chain, regarding technological innovation as the vital backbone for fostering high-quality enterprise development. The company’s R&D investment now accounts for nearly 10% of its main business revenue, strongly propelling the enterprise onto the fast track of innovative growth. To date, the company ranks among the top in China’s pharmaceutical industry in terms of innovative research on generic drugs. The accelerated implementation of these innovative achievements continuously injects new momentum into the company’s high-quality development, powerfully promoting and driving structural optimization of the product chain and upgrading of market positioning, thereby helping the company accelerate its transformation and upgrade and move toward the mid-to-high end of the value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license